Moving Beyond Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Cancer: Latest Evidence and Therapeutic Implications

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2017 May 12

PMID 28491148

Citations 5

Authors

Che-Kai Tsao

Bobby Liaw

Catherine He

Matthew D Galsky

John Sfakianos

William K Oh

Affiliations

Soon will be listed here.

Abstract

Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC.

Citing Articles

Identification of novel snoRNA-based biomarkers for clear cell renal cell carcinoma from urine-derived extracellular vesicles.

Grutzmann K, Salomo K, Kruger A, Lohse-Fischer A, Erdmann K, Seifert M Biol Direct. 2024; 19(1):38.

PMID: 38741178 PMC: 11089706. DOI: 10.1186/s13062-024-00467-0.

Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.

Yang S, Yang X, Hou Z, Zhu L, Yao Z, Zhang Y Heliyon. 2024; 10(7):e29215.

PMID: 38623200 PMC: 11016731. DOI: 10.1016/j.heliyon.2024.e29215.

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.

Schmidinger M, Motzer R, Rolland F, Staehler M, Rink M, Retz M Acta Oncol. 2021; 61(1):52-57.

PMID: 34736367 PMC: 9357268. DOI: 10.1080/0284186X.2021.1995041.

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment.

van Beijnum J, Weiss A, Berndsen R, Wong T, Reckman L, Piersma S Cancers (Basel). 2020; 12(9).

PMID: 32967224 PMC: 7564658. DOI: 10.3390/cancers12092697.

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo R, Kolenko V Mol Cancer Ther. 2018; 17(7):1355-1364.

PMID: 29967214 PMC: 6034114. DOI: 10.1158/1535-7163.MCT-17-1299.

References

Flaherty K, Manola J, Pins M, Mcdermott D, Atkins M, Dutcher J . BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the.... J Clin Oncol. 2015; 33(21):2384-91. PMC: 4500832. DOI: 10.1200/JCO.2015.60.9727. View

Zhou L, Liu X, Sun M, Zhang X, German P, Bai S . Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2015; 35(21):2687-97. PMC: 4791213. DOI: 10.1038/onc.2015.343. View

Baldewijns M, van Vlodrop I, Vermeulen P, Soetekouw P, van Engeland M, de Bruine A . VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010; 221(2):125-38. DOI: 10.1002/path.2689. View

Kirner A, Mayer-Mokler A, Reinhardt C . IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2015; 10(11):3179-89. PMC: 4514142. DOI: 10.4161/21645515.2014.983857. View

Carbonaro M, OBrate A, Giannakakou P . Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol. 2011; 192(1):83-99. PMC: 3019555. DOI: 10.1083/jcb.201004145. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Thompson R, Kuntz S, Leibovich B, Dong H, Lohse C, Webster W . Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66(7):3381-5. DOI: 10.1158/0008-5472.CAN-05-4303. View

Motzer R, Hutson T, McCann L, Deen K, Choueiri T . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014; 370(18):1769-70. DOI: 10.1056/NEJMc1400731. View

Attig S, Hennenlotter J, Pawelec G, Klein G, Koch S, Pircher H . Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 2009; 69(21):8412-9. DOI: 10.1158/0008-5472.CAN-09-0852. View

10.

Hutson T, Escudier B, Esteban E, Bjarnason G, Lim H, Pittman K . Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2013; 32(8):760-7. PMC: 5569683. DOI: 10.1200/JCO.2013.50.3961. View

11.

Rini B, Szczylik C, Tannir N, Koralewski P, Tomczak P, Deptala A . AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012; 118(24):6152-61. PMC: 4666535. DOI: 10.1002/cncr.27632. View

12.

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

13.

Molina A, Hutson T, Larkin J, Gold A, Wood K, Carter D . A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2013; 73(1):181-9. PMC: 3889692. DOI: 10.1007/s00280-013-2339-y. View

14.

Soultati A, Stares M, Swanton C, Larkin J, Turajlic S . How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Curr Opin Urol. 2015; 25(5):358-66. DOI: 10.1097/MOU.0000000000000204. View

15.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

16.

Lokich J . Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol. 1997; 20(4):416-8. DOI: 10.1097/00000421-199708000-00020. View

17.

Walpole E, Dutcher J, Sparano J, Gucalp R, Einzig A, Paietta E . Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother Emphasis Tumor Immunol. 1993; 13(4):275-81. DOI: 10.1097/00002371-199305000-00007. View

18.

Gulati S, Martinez P, Joshi T, Birkbak N, Santos C, Rowan A . Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol. 2014; 66(5):936-48. PMC: 4410302. DOI: 10.1016/j.eururo.2014.06.053. View

19.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg C . Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014; 32(14):1412-8. DOI: 10.1200/JCO.2013.50.8267. View

20.

Yang J, Hughes M, Kammula U, Royal R, Sherry R, Topalian S . Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30(8):825-30. PMC: 2134980. DOI: 10.1097/CJI.0b013e318156e47e. View